- TXG is a life sciences company trading at 58x P/S and 23x P/B, with a history of negative earnings.
- The current market price is implying that the company already has 25% of the life sciences research tools market; in reality, it only has 0.5%.
- Insiders have been consistently selling heavily over the past year.
- The company also faces litigation risks, which may prohibit it from selling its products altogether.
- High valuations, heavy insider selling, small market position, unknown litigation risks and an exciting new field all point to one thing: an overpriced stock that risks permanent loss of capital.
For further details see:
10x Genomics: Wouldn't Touch This, Even With A 10x10 Foot Pole